{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:59:27Z","timestamp":1791338367719,"version":"4.3.1"},"reference-count":33,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Fibroblast growth factor receptor 1 (<jats:italic>FGFR1<\/jats:italic>) amplification is a potential driving oncogene in squamous cell cancer (SCC) of the lung. The current phase 2 study evaluated the efficacy and tolerability of dovitinib, an FGFR inhibitor, in patients with advanced SCC of the lung.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with pretreated advanced SCC of the lung whose tumors demonstrated <jats:italic>FGFR1<\/jats:italic> amplification of\u2009&gt;\u20095 copies by fluorescence in situ hybridization were enrolled. Dovitinib at a dose of 500\u2009mg was administered orally, once daily, on days 1 to 5 of every week, followed by 2 days off. The primary endpoint was overall response. Secondary endpoints were progression\u2010free survival, overall survival, and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>All 26 patients were men with a median age of 68 years (range, 52\u201080 years). The majority of patients were ever\u2010smokers. The median duration of dovitinib administration (28 days per cycle) was 2.5 months (range, 0.7\u20108.6 months). The overall response rate was 11.5% (95% confidence interval [95% CI], 0.8%\u201023.8%) and the disease control rate was 50% (95% CI, 30.8%\u201069.2%), with 3 patients achieving partial responses. Response durations for the patients with partial responses were \u22654.5 months,\u2009\u2265\u20095.1 months, and 6.1 months, respectively. After a median follow\u2010up of 15.7 months (range, 1.2\u201025.6 months), the median overall survival was 5.0 months (95% CI, 3.6\u20106.4 months) and the median progression\u2010free survival was 2.9 months (95% CI, 1.5\u20104.3 months). The most common grade 3 or higher adverse events were fatigue (19.2%), anorexia (11.5%), and hyponatremia (11.5%) (event severity was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Treatment with dovitinib demonstrated modest efficacy in patients with advanced SCC with <jats:italic>FGFR1<\/jats:italic> amplification. Further studies to evaluate other biomarkers correlated with the efficacy of dovitinib in patients with SCC are warranted. <jats:bold><jats:italic>Cancer<\/jats:italic> 2016;122:3024\u20103031<\/jats:bold>. \u00a9 <jats:italic>2016 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30135","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T16:28:51Z","timestamp":1466180931000},"page":"3024-3031","source":"Crossref","is-referenced-by-count":77,"title":["Efficacy and safety of dovitinib in pretreated patients with advanced squamous non\u2010small cell lung cancer with <i>FGFR1<\/i> amplification: A single\u2010arm, phase 2 study"],"prefix":"10.1002","volume":"122","author":[{"given":"Sung Hee","family":"Lim","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong\u2010Mu","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon\u2010La","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Translational Genomics, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center Yonsei University College of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomin","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Pathology and Translational Genomics, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u2010Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hang","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center Yonsei University College of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center Yonsei University College of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung\u2010Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2011.08.005"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu123"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2095"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61758-4"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2370"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3039"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2780"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001451"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020351"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.05.020"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70190-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2885"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182a46fe9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.345215"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.102"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.141"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3060"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3006"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3357"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0190"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8622"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.58"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.002"},{"key":"e_1_2_8_31_1","article-title":"A phase 1b open\u2010label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: preliminary antitumor activity and pharmacodynamic data [abstract]","volume":"32","author":"Paik PK","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8034","article-title":"Targeting FGFR1\u2010amplified lung squamous cell carcinoma with the selective pan\u2010FGFR inhibitor BGJ398 [abstract]","volume":"32","author":"Nogova L","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.013"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30135","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:21:36Z","timestamp":1760296896000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/cncr.30135"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30135","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,17]]}}}